Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a Phase 2 trial registration with no results posted; it describes planned enrollment and outcome measures only, representing early-stage efficacy and safety evaluation of an investigational agent.
Phase 2 trial of an investigational agent for bipolar depression with surrogate mood and safety endpoints; study is actively recruiting with no results posted.
This is a Phase 1/2 trial registration with no reported results; it describes a planned safety and dose-escalation study in a small population with surrogate endpoints (amyloid imaging) and safety assessments only.
This is an active Phase 2 trial registration with no results reported; the study is designed to assess safety and efficacy of telisotuzumab vedotin in previously treated NSCLC but enrollment and follow-up are ongoing.
This is an ongoing Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
This is a Phase 1/2 trial registration with no posted results; it describes a planned dose-escalation and optimization study in a treatment-naive population, representing early-stage investigation of a novel combination.
Phase 1 safety and tolerability study in healthy volunteers with no results posted; designed to characterize adverse events and pharmacokinetics of a novel agent, not efficacy or clinical benefit.
FDA supplemental labeling approval for an established antiretroviral combination; regulatory action confirms labeling changes but does not report new clinical trial data or efficacy evidence.